Blog
Oncolytic Virus/CAR T-Cell Therapy Combo Shows Preclinical Potential in Solid Tumors
Solid tumors are surrounded by an immunosuppressive tumor microenvironment. Therefore,
July 6, 2021
Menu
Solid tumors are surrounded by an immunosuppressive tumor microenvironment. Therefore,
The CAR T-cell therapy idecabtagene vicleucel (ide-cel; Abecma) continues to
Alternative oxidase (AOX) has been identified as a potential therapeutic
The first CAR-T immunotherapy directed against BCMA (idecabtagene vicleucel) for
Australian company, Vaxine Pty Ltd, has developed a protein-based COVID-19
ALLO-501A is a CAR T cell-based therapy for relapsed or
According to scientists at the Medical College of Georgia, a
The development of CAR T cells is one of the
Multiple myeloma is the second most common hematological malignancy in
